Raul R. Rodriguez - 24 Jan 2025 Form 4 Insider Report for RIGEL PHARMACEUTICALS INC (RIGL)

Role
CEO, President, Director
Signature
/s/ Raymond Furey (Attorney-in-Fact)
Issuer symbol
RIGL
Transactions as of
24 Jan 2025
Net transactions value
-$28,419
Form type
4
Filing time
28 Jan 2025, 20:49:28 UTC
Previous filing
26 Nov 2024
Next filing
31 Jan 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RIGL Common Stock Options Exercise $963,000 +45,000 +22% $21.40 249,662 24 Jan 2025 Direct F1, F2
transaction RIGL Common Stock Tax liability $977,209 -44,078 -18% $22.17 205,584 24 Jan 2025 Direct
transaction RIGL Common Stock Options Exercise $963,000 +45,000 +22% $21.40 250,584 24 Jan 2025 Direct F1
transaction RIGL Common Stock Tax liability $977,209 -44,078 -18% $22.17 206,506 24 Jan 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RIGL Employee Stock Option (right to buy) Options Exercise $0 -45,000 -100% $0.000000 0 24 Jan 2025 Common Stock 45,000 $21.40 Direct F1, F3
transaction RIGL Employee Stock Option (right to buy) Options Exercise $0 -45,000 -100% $0.000000 0 24 Jan 2025 Common Stock 45,000 $21.40 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024.
F2 Includes 1,000 shares acquired under the Issuer's stock purchase plan.
F3 The shares vested monthly over two (2) years from January 1, 2015.